Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases
about
Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancerMedical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancerThe Crossroads of Geriatric Cardiology and Cardio-OncologyTaxanes in the elderly patient with metastatic breast cancerSerum biomarkers for the detection of cardiac toxicity after chemotherapy and radiation therapy in breast cancer patientsDaunorubicin, amsacrine, and sinus arrestDietary red palm oil protects the heart against the cytotoxic effects of anthracyclineMedical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer.Model-based contextualization of in vitro toxicity data quantitatively predicts in vivo drug response in patients.Cardiomyocyte death in doxorubicin-induced cardiotoxicityAnthracyclines and the heart.Anthracyclines: cardiotoxicity and its prevention.A critical risk-benefit assessment argues against the use of anthracyclines in induction regimens for newly diagnosed childhood acute lymphoblastic leukemia.Secondary alcohol metabolites mediate iron delocalization in cytosolic fractions of myocardial biopsies exposed to anticancer anthracyclines. Novel linkage between anthracycline metabolism and iron-induced cardiotoxicityDexrazoxane for the treatment of chemotherapy-related side effects.Cardiovascular effects in childhood cancer survivors treated with anthracyclines.Anthracycline-associated cardiotoxicity in survivors of childhood cancer.Cardiotoxicity and oncological treatments.Amsacrine (m-AMSA): a new antineoplastic agent. Pharmacology, clinical activity and toxicity.Early identification of anthracycline cardiomyopathy: possibilities and implications.2010 Riley Heart Center Symposium on Cardiac Development: cardiomyocyte injury and protectionApoptosis in Anthracycline CardiomyopathyEquivalence Ratio for Daunorubicin to Doxorubicin in Relation to Late Heart Failure in Survivors of Childhood Cancer.Hematopoietic stem cell transplantation in patients with systolic dysfunction: can it be done?Chemotherapy induced cardiomyopathy: pathogenesis, monitoring and managementCoenzyme q10 for prevention of anthracycline-induced cardiotoxicity.Late Cardiac Events after Childhood Cancer: Methodological Aspects of the Pan-European Study PanCareSurFupIron chelators with topoisomerase-inhibitory activity and their anticancer applications.A phase I study of intravenous liposomal daunorubicin (DaunoXome) in paediatric patients with relapsed or resistant solid tumours.Anthracycline cardiotoxicity.Cardiovascular Toxicity of Molecular Targeted Therapy in Cancer Patients: A Double-Edged SwordRole of non-transferrin bound iron in iron overload and liver dysfunction in long term survivors of acute leukaemia and bone marrow transplantationCardiorespiratory fitness in breast cancer patients: a call for normative values.Can anthracycline therapy for pediatric malignancies be less cardiotoxic?Clinical nanomedicine: a solution to the chemotherapy conundrum in pediatric leukemia therapy.Topoisomerase 2β: a promising molecular target for primary prevention of anthracycline-induced cardiotoxicity.Cardiomyopathy associated with cancer therapy.Left ventricular strain and strain rates are decreased in children with normal fractional shortening after exposure to anthracycline chemotherapy.Anthracycline-Induced Cardiomyopathy in Adults.Heart failure and chemotherapeutic agents.
P2860
Q24234511-3EC1B343-2976-4C5E-9DD5-3E99DCDE388AQ24241097-3F5425AF-4436-4126-8703-9576158C6E31Q26778666-90ACD96E-2E36-4BF1-B321-B27723D5E245Q26785458-25AE20D5-5181-4985-BED9-9531D90A73FAQ27007849-041EBBFA-A0C2-4C68-AF25-74ED6353C1FDQ28332838-0E2F6EAC-5004-4513-AC6B-1DF9C772F8B4Q28583225-2CBE3E8D-EB2D-47D5-BED4-3212C81BC2D8Q30248340-DC975025-6217-4D19-8622-A58DE585BD56Q30838395-BD4929BC-BB20-4CBE-8071-7D9943DD9454Q33604134-E3E26B4D-4DFB-411B-88EC-7AE2EFF72AB9Q33613628-47AE068E-1DCB-44E8-B64D-CCF7922C6CD6Q33625243-6199B4E8-66AF-4DC2-92CC-4CCF14EC659AQ33735167-03F1455A-6D93-46AD-A864-C8050EB05B5EQ34207581-4809AECE-69A1-4DE0-B2C2-C4ACF0275C00Q34211957-A9F2D6C0-F3E7-4095-AC21-7CB7928CD386Q34572109-AC73188F-7F51-4890-9632-68A07583974EQ34626238-92B4B686-0F8D-4701-8287-B314A139621EQ34660647-FD74186D-A71A-4F1B-AA83-B42B6714D191Q34669034-F63FA243-C1CC-4A14-A982-00732EE410E1Q34800157-78C70A34-7522-43FC-A4A3-085F237C33B0Q35414698-C0A64EE8-6008-4520-83CF-3BE50D5DAF5EQ35642302-FD4B9E67-416C-49F3-BB2B-EAA53132383DQ35754395-D49B4353-8483-4040-86C8-39EFD2CE6F71Q35843555-FDCFBB14-385B-478C-9AC6-105D347A12F6Q35868495-DAC4504C-8F20-4A33-8AD7-930AA0B6DFC9Q36136382-4652F3A0-5C05-40E4-84FC-EFD1CDE69738Q36137174-93B46BB7-C819-43FD-91CA-89F075555DEEQ36568915-B13267D9-121A-4D42-865B-286F62647491Q36612320-4D5D8F18-6CB7-4024-9EB3-A32D7F3A7F5AQ36624983-4E03C0D9-2557-44FB-A52D-77B914250204Q36721511-202FF94F-4CEE-4E79-BAEA-0F87A8E6C178Q37224329-D03968D8-D750-4559-B687-258563850268Q37648469-88A2A35C-1DAE-44BC-BB18-D80C9F1D49DCQ37785821-B8183738-5F25-4F89-9F15-6F6B0BF7959FQ38135276-B9ED495E-5943-4189-B802-1040EED83EF8Q38148968-C03587D5-FD23-4FD6-AB8F-30742BB33986Q38242641-B669291F-6F39-4217-A840-982B8B0110C5Q38446817-8ADCB888-2960-44B6-A88B-D30F637ED3ABQ38542462-02AEA134-D0BC-4505-B03F-2CA78FA1D5E5Q38559133-93F4EC86-ECAD-4D99-8144-8C21283E73E3
P2860
Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases
description
1977 nî lūn-bûn
@nan
1977 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1977 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1977年の論文
@ja
1977年論文
@yue
1977年論文
@zh-hant
1977年論文
@zh-hk
1977年論文
@zh-mo
1977年論文
@zh-tw
1977年论文
@wuu
name
Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases
@ast
Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases
@en
Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases
@nl
type
label
Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases
@ast
Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases
@en
Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases
@nl
prefLabel
Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases
@ast
Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases
@en
Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases
@nl
P2093
P3181
P1476
Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases
@en
P2093
D D Von Hoff
F M Muggia
M Rozencweig
P3181
P356
10.1016/0002-9343(77)90315-1
10.1016/0002-9343(77)90331-X
P407
P577
1977-02-01T00:00:00Z